

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/676,691
Filing Date	September 30, 2003
First Named Inventor	Veneta Hanson
Art Unit	1641
Examiner Name	J. Grun
Attorney Docket Number	0028/71160/JPW/BJA

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JLG	1	Bresnihan, B. et al., (1979), An Antineuronal Antibody Cross-Reacting with Erythrocytes and Lymphocytes in systemic Lupus Erythematosus, Arthritis and Rheumatism, 22(4):313-	
	2	Burton, R. et al., (1971), Immunological Disorders of the Nervous System, Res. Publ. Assoc. Res. Nerv. Ment. Dis., 49:197-214;	
	3	Denburg, J. et al., (1983), The Pathogenesis of Neuropsychiatric Lupus, Can. Med. Assoc. J., 128:257-260;	
	4	Gitlits, V. et al., (1997), Autoantibodies to Evolutionarily Conserved Epitopes of Enolase in a Patient with Discoid Lupus Erythematosus, Immunology, 92:362-368;	
	5	Gitlits, V. et al., (2001), Disease Association, Origin, and Clinical Relevance of Autoantibodies to the Glycolytic Enzyme Enolase, J. Inv. Med., 49(2):138-145;	
	6	Hanson, V. et al., (1992), Systemic Lupus Erythematosus Patients with Central Nervous System Involvement Show Autoantibodies to a 50-kD Neuronal Membrane Protein, J. Exp. M	
	7	Johnson, R. et al., (1968), The Neurological Manifestations of Systemic Lupus Erythematosus, Medicine, 47(4):337-369;	
	8	Krüger, K. (1984), Lupus Erythematosus Und Zentralnervensystem; Abstract only.	
	9	López-Méndez, A. et al., (1986), Neurological Involvement in Systemic Lupus Erythematosus, Immunological and Clinical Aspects, Bol. Asoc. Med. P. Rico, 78(3):99-103;	
JLG	10	Pratesi, F. et al., (2000), Autoantibodies Specific for α-Enolase in Systemic Autoimmune Disorders, J. Rheum., 27:109-115;	


Examiner Signature	/James L. Grun/	Date Considered	06/13/2006
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: Veneta Hanson et al.
U.S. Serial No.: 10/676,691
Filed: September 30, 2003
Exhibit A



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/676,691
Filing Date	September 30, 2003
First Named Inventor	Veneta Hanson
Art Unit	1641
Examiner Name	J. Grun
Attorney Docket Number	0028/71160/JPW/BJA

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JLG	11	Quismorio, F. et al., (1972), Antibodies Reactive with Neurons in SLE Patients with Neuropsychiatric Manifestations, Int. Arch. Allergy, 43:740-748;	
JLG	12	Schott, K. et al., (1998), Antibrain Antibodies in Mental Disorder: No evidence for Antibodies Against Synaptic Membranes, J. Neural. Transm., 517-524; and	
JLG	13	Wilson, H. (1979), Association of IgG Anti-Brain Antibodies with Central Nervous System Dysfunction in Systemic Lupus Erythematosus, Arthritis and Rheumatism, 22(5):458-46.	

Examiner Signature	/James L. Grun/	Date Considered	06/13/2006
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.